Base Year
Historical Year
Forecast Year
The global BREO ellipta drugs market is driven by the growing chronic obstructive pulmonary disease drugs market, which is likely to grow at a rate of 4.5% during the forecast period of 2024-2032. The prevalence of these respiratory disease is expected to rise significantly over the coming years due to rising pollution levels, along with other factors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pharmaceutical market for asthma and other respiratory diseases has increased by manifolds in the past few years due to the poor air quality across majority of the region. The BREO ellipta drug is one such drug and is approved for asthma patients over the age of 18 years. It is a prescription only powder inhaler which is used for one inhalation for one time each day to ease and control the symptoms of asthma to a significant extent. It helps the breathing process and controls wheezing.
The drug contains vilanterol, which is a long-acting beta2-adrenergic agonist (LABA) medicine and can be fatal if used alone. This is why BREO contains a combination of inhaled corticosteroid (ICS) called fluticasone and a long-acting beta2-adrenergic agonist, which reduces the risk of any fatal effects. Fluticasone helps in reducing the swelling in the lungs. On the other hand, Vilanterol aids in the relaxation of muscles around the airways and can ease the process of breathing. While the drug is extremely effective if used regularly as per the doctor’s prescription, it needs to be used responsibly and not for sudden asthma attacks as it does not work as fast as a rescue inhaler.
Along with asthma patients, the BREO ellipta drug is also used in patients suffering from any other lung diseases like chronic obstructive pulmonary diseases (COPD) like chronic bronchitis and emphysema.
The drug also poses the threats of multiple side-effects. Some of these potential side-effects include choking, wheezing, fast or pounding heartbeats or any sort of pounding in the neck or ears, sores or white patches in the mouth and throat, pain when swallowing, fever, chills, cough with yellow or green mucus, blurred vision, eye pain, or seeing halos around lights, high blood sugar, increased thirst and urination, frequent cramps, constipation, muscle weakness or limp feeling, signs of a hormonal disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market can be divided on the basis of indication type, mode of administration, distribution channel, and major regions.
Market Breakup by Indication Type
Market Breakup by Mode of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The BREO Ellipta drugs market has been on a rise, especially since the prevalence of respiratory disease increased since the coronavirus pandemic. It triggered the respiratory issues amongst the people across the globe. The drug is still not affordable for a lot of people as most of the patients are from the rural areas. COPD affects more than 300 million people globally and about 3 million of these people are affected due to air pollution in households and more than 14% of these cases are caused due to the occupational environment and exposures. While most of the patients belong to rural areas, urban areas also witness significant exposure to COPD. In terms of smoking habit, more than 40% of the patients are people who have never smoked in their life.
The report gives an in-depth analysis of the key players involved in the BREO Ellipta drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Mode of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is likely to be driven by the rising chronic obstructive pulmonary disease drugs market, which is expected to grow at a CAGR of 4.5% during the forecast period of 2024-2032.
The growth of the market is primarily driven by the rising respiratory diseases like asthma and COPD, among others.
The key trends in the market include the rising cases of asthma induced by the rising pollution across the globe.
The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The segmentation on the basis of indication type includes chronic obstructive pulmonary disease (COPD), cystic fibrosis, chronic bronchitis, and asthma, among others.
The modes of administration include dry powder inhaler, Respimat soft mist inhaler, pressurized metered dose inhaler, and nebulizers, among others.
The distribution channels include hospital-based pharmacies, online pharmacies, and retail pharmacies.
The key companies involved in the market are GSK plc, Akros Pharma Inc, Sun Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Abbott, and Genosco Inc., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share